Improved surgical margins with neoadjuvant versus adjuvant chemotherapy in clinical stage I resectable pancreatic adenocarcinoma: A National Cancer Database study.
651 Background: A strengthening consensus exists for neoadjuvant therapy (NAT) in borderline resectable pancreatic adenocarcinoma (PA), but the utilization of NAT in resectable stage I PA remains controversial. Many cancer centers are using NAT for these patients (pts), but others continue to offer upfront surgery and adjuvant therapy (AT). We hypothesized that NAT would improve margin negative…
